Meeting
2020 Gastrointestinal Cancers Symposium
First-line drug selection versus sequential treatment in advanced pancreatic cancer: Does it really matter? Multi-institutional Canadian perspective.
Authors
Ivan Barrera
Jewish General Hospital, McGill University, Montreal, QC, Canada
Ivan Barrera , Neha Papneja , Jill Ranger , Abhishek Papneja , Petr Novotny , Shahid Ahmed , Gerald Batist , Petr Kavan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 673)
Abstract #
673
Poster Bd #
J4
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) as first-line treatment for de novo metastatic pancreatic cancer (MPC): Safety and effect.
First Author: Brett A. Schroeder
Poster
2014 ASCO Annual Meeting
Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy.
First Author: Thomas H. Cartwright
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer.
First Author: Bomi Kim
Poster
2018 ASCO Quality Care Symposium
Treatment patterns, toxicity, and outcomes of elderly patients with advanced pancreatic cancer receiving first-line chemotherapy.
First Author: Robert Kudlovich